Nivolumab (Opdivo®) is the world’s first monoclonal antibody to be approved that targets PD-1, and it has significant therapeutic effects in patients with recurrence or metastasis (R/M) of HNSCC. Here, PDCD1 is linked to head and neck squamous cell carcinoma.